Sort publications on year

  • Pharmaco-Economics

    Modelling lifetimes cost consequences of RESTOR for presbyopia in four European countries

    LAFUMA A, BERDEAUX G

    Eye ; 23(5):1072-80

  • Pharmaco-Economics

    Epidemiolgy, medical outcomes and costs of catheter-related bloodstream infections in intensive care units of European countries : literature-and registry-based estimates

    TACCONELLI E, SMITH G, HIEKE K, LAFUMA A, BASTIDE P

    J Hosp Infect ; 2009;72(2):97-103

  • Pharmaco-Economics

    Economics and attitudes regarding spectacles in daily life : a European perspective

    Economics and attitudes regarding spectacles in daily life : a European perspective

    Ophthalmic Epidemiol ; 16(4):218-223

  • Pharmaco-Economics

    Coûts des soins remboursés par l’assurance maladie aux personnes traitées pour diabète : Etudes Entred 2001 et 2007

    RICCI P, CHANTRY M, DETOURNAY B, POUTIGNAT N, KUSNIK-JOINVILLE O, RAIMOND V, THAMMAVONG N, WEILL A

    Bull Epidemiol Hebd ; 42-43:464-469

  • Pharmaco-Economics

    Cost of cataract surgery after implantation of three intraocular lenses

    BOUREAU C, LAFUMA A, JEANBAT V, SMITH AF, BERDEAUX G

    Clin Ophtalmol ; 3:277-285

  • Pharmaco-Economics

    Cost effectiveness of Travoprost versus a Fixed Combination of Latanoprost/Timolol in Patients with Ocular Hypertension or Glaucoma : Analysis Based on the UK General Practitioner Research DataBase

    DE NATALE R, LAFUMA A, BERDEAUX G

    Clin Drug Investig ; 29(2):111-120

  • Pharmaco-Economics

    Bénéfice économique de Pradaxa® en thromboprophylaxie après prothèse totale de hanche ou de genou

    BOUÉE S, ZUFFEREY P, FAGNANI F

    Thérapie ; 64(4):249-257

  • Pharmaco-Economics

    Modelling lifetimes cost consequences of RESTOR in cataract surgery in four European countries

    LAFUMA A, BERDEAUX G

    BMC Ophtalmol ; 8(1):12

  • Pharmaco-Economics

    La prise en charge médicale et chirurgicale de l’obésité : le contexte médico-économique

    DETOURNAY B

    Technologie&Santé ; (66):19-22

  • Pharmaco-Economics

    Etude pharmaco-économique sur la prise en charge du reflux gastro-oesophagien en France en 2005 en médecine générale

    MOULY S, CHARLEMAGNE A, LE JEUNNE PH, FAGNANI F

    Presse Med ; 37:1397-1406

  • Pharmaco-Economics

    Costs and persistence of carbonic anhydrase inhibitor versus alpha2 agonists, associated with beta-blockers, in glaucoma an ocular hypertension : an analysis of the UKGPRD database

    LAFUMA A, BERDEAUX G

    Curr Med Res Opin ; 24(5):1519-1527

  • Pharmaco-Economics

    Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care : an analysis conducted on the UK General Practitioner Research Database

    LAFUMA A, LAURENDEAU C, BERDEAUX G

    J Med Econ ; 11(3):485-497

  • Pharmaco-Economics

    Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by the United Kingdom General Practitioner Research Database

    DENIS P, LAFUMA A, BERDEAUX G

    Clin Ophtalmol ; 2(2):321-329

  • Pharmaco-Economics

    Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients : A French adaptation of CARDS

    LAFUMA A, COLIN X, SOLESSE A

    Arch Cardiovasc Dis ; 2008;101(5):327-332

  • Pharmaco-Economics

    Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France

    STANDAERT B, PAREZ N, TEHARD B, COLIN X, DETOURNAY B

    Appl Health Econ Health Policy ; 6(4):199-216